These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31757568)

  • 1. Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):71-76. PubMed ID: 31757568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class effect for SGLT-2 inhibitors: a tale of 9 drugs.
    Giugliano D; Esposito K
    Cardiovasc Diabetol; 2019 Jul; 18(1):94. PubMed ID: 31337395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
    Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney.
    Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Garofalo C; Chiodini P; Ceriello A; Esposito K
    Cardiovasc Diabetol; 2020 Mar; 19(1):35. PubMed ID: 32192503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand.
    Cavallari I; Maddaloni E
    Diabetes Metab Res Rev; 2019 May; 35(4):e3124. PubMed ID: 30604504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.
    Grenet G; Ribault S; Nguyen GB; Glais F; Metge A; Linet T; Kassai-Koupai B; Cornu C; Bejan-Angoulvant T; Erpeldinger S; Boussageon R; Gouraud A; Bonnet F; Cucherat M; Moulin P; Gueyffier F
    PLoS One; 2019; 14(6):e0217701. PubMed ID: 31237921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
    Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
    Seidu S; Kunutsor SK; Sesso HD; Gaziano JM; Buring JE; Roncaglioni MC; Khunti K
    Cardiovasc Diabetol; 2019 Jun; 18(1):70. PubMed ID: 31159806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Papadopoulos C; Kassimis G; Fragakis N; Vassilikos V; Karagiannis A; Doumas M
    Vasc Med; 2022 Oct; 27(5):433-439. PubMed ID: 35754338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 16. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
    Gelbenegger G; Postula M; Pecen L; Halvorsen S; Lesiak M; Schoergenhofer C; Jilma B; Hengstenberg C; Siller-Matula JM
    BMC Med; 2019 Nov; 17(1):198. PubMed ID: 31679516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
    Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
    Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
    Pintat S; Fenici P; Hammar N; Ji L; Khunti K; Medina J; Tang F; Wittbrodt E; Surmont F
    BMJ Open Diabetes Res Care; 2019; 7(1):e000627. PubMed ID: 31114700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of the CANVAS Study in Reducing Cardiovascular Outcomes.
    Madan Paramasivan A; Purushothaman A; Desouza C
    Curr Diab Rep; 2018 Nov; 18(12):142. PubMed ID: 30397837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials.
    Giugliano D; Longo M; Maiorino MI; Bellastella G; Chiodini P; Solerte SB; Esposito K
    Diabetes Res Clin Pract; 2020 Apr; 162():108114. PubMed ID: 32165164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.